Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
FDA Approves Pembrolizumab for Advanced Melanoma
September 4th 2014The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.
Read More
Subtype, pCR Predict Locoregional Recurrence Following Neoadjuvant Therapy
September 2nd 2014The combination of multiple independent factors minimized the impact of baseline stage for predicting locoregional recurrence (LRR) following neoadjuvant chemotherapy in patients with breast cancer, according to a large retrospective analysis presented in advance of the 2014 Breast Cancer Symposium.
Read More
FDA Approval Sought for Lenvatinib in Differentiated Thyroid Cancer
August 31st 2014Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.
Read More
FDA Expands Bortezomib Multiple Myeloma Label
August 11th 2014The FDA has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor, according to an announcement made by Millennium/Takeda, the companies that manufacture the drug.
Read More
Carfilzomib Combination Effective for Relapsed Myeloma
August 4th 2014The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma
Read More
Search for Curative Therapies Continues in Lung Cancer
August 1st 2014Curative strategies for patients with advanced lung cancer remain elusive despite several exciting advancements, according to Paul A. Bunn Jr, MD, and Primo N. Lara Jr, MD, who delivered keynote lectures during the 15th Annual International Lung Cancer Congress.
Read More
Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study
July 23rd 2014Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab
Read More
Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer
July 21st 2014The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.
Read More
Novel Therapies, Strategies in Development for NSCLC
July 16th 2014The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.
Read More